Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XS005 Combined With Stupp Regimen in Primary Glioblastoma
NCT06147505Phase 2Active, not recruiting
- Sponsor
- Soochow University
- Start
- Oct 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XS005 Sorafenib-ASD in glioblastoma (GBM), sponsored by Soochow University. Primary endpoints: Incidence of Dose-Limiting Toxicities at 7 days, Incidence of Adverse Events at 4 months and 1 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
XS005 Sorafenib-ASD
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06147505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06147505.